Abbott Q2 Earnings Report: Key Metrics Revealed

Abbott reported Q2 revenue of $11.14 billion, up 7.4% YoY, and EPS of $1.26, compared to $1.14 in the year-ago quarter. Key metrics showed a year-over-year change of -0.1% in US diagnostics net sales, +3.1% in international nutrition net sales, and +6.9% in established pharmaceuticals net sales. Medical devices sales also showed significant growth, with diabetes care up 20.2% and structural heart and heart failure up 12.8% and 14.6%, respectively.

Title: Abbott's Q2 2025 Financial Results: Strong Sales Growth and Margin Expansion

Abbott (NYSE: ABT) reported its second-quarter 2025 financial results, showcasing robust sales growth and margin expansion across various business segments. The company's revenue for the quarter totaled $11.14 billion, up 7.4% year-over-year (YoY) [1]. This growth was driven by strong performance in Medical Devices, Established Pharmaceuticals, and Adult Nutrition segments.

Medical Devices, one of Abbott's key growth engines, reported a 12% organic increase in sales, marking its 10th consecutive quarter of double-digit growth. Diabetes Care sales surged by 19%, with the U.S. market contributing significantly to this growth. Additionally, double-digit growth was observed in Heart Failure, Structural Heart, and Electrophysiology segments [1].

Established Pharmaceuticals sales grew almost 8% on an organic basis, with notable increases in several countries across Asia, Latin America, and the Middle East. Adult Nutrition, bolstered by strong demand for Ensure and Glucerna, posted more than 6% organic growth, leading overall Nutrition sales performance [1].

The company's adjusted diluted earnings per share (EPS) for the quarter was $1.26, reflecting double-digit growth compared to the prior year. Abbott narrowed its full-year 2025 adjusted diluted EPS guidance to $5.10 to $5.20, indicating continued strong financial performance [1].

Abbott's second-quarter results also highlighted significant margin expansion. The company reported an adjusted gross margin of 57.0% and an adjusted operating margin of 22.9%, reflecting a 100 basis point increase compared to the prior year [2].

Key metrics showed a year-over-year change of -0.1% in US diagnostics net sales, +3.1% in international nutrition net sales, and +6.9% in established pharmaceuticals net sales. Medical devices sales demonstrated significant growth, with diabetes care up 20.2% and structural heart and heart failure up 12.8% and 14.6%, respectively [2].

In addition to its financial results, Abbott continued to advance its pipeline with purpose, delivering on its mission to broaden the impact of its breakthrough technologies. Notable milestones include the completion of enrollment in the U.S. IDE trial for the TactiFlex™ Duo Pulsed Field Ablation (PFA) System, the announcement of clinical data from the AVEIR™ Conduction System Pacing (CSP) feasibility study, and the receipt of FDA approval for its Tendyne™ transcatheter mitral valve replacement (TMVR) system [1, 2].

Abbott's strong Q2 2025 results position the company well for continued growth and margin expansion in the coming quarters. The company's focus on innovation and market leadership in key healthcare segments is expected to drive future performance.

References:
[1] https://www.abbott.com/corpnewsroom/strategy-and-strength/abbotts-diversified-healthcare-leadership-fuels-q2-results.html
[2] https://abbott.mediaroom.com/2025-07-17-Abbott-Reports-Second-Quarter-2025-Results